Shanghai Weihe Medical Laboratory Co., Ltd.
6
3
3
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
ProSight: a Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
Role: lead
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
Role: collaborator
Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC )
Role: collaborator
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection（PROFOUND）
Role: lead
Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach
Role: collaborator
PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection
Role: collaborator
All 6 trials loaded